Comparative effects of milbemycin oxime-based and febantel-pyrantel embonate-based anthelmintic tablets on Toxocara canis egg shedding in naturally infected pups.
The effect of two treatment programmes on egg shedding in dogs naturally infected with Toxocara canis, one based on a milbemycin oxime-praziquantel-lufenuron combination (SENTINEL) Spectrum; Group 1) and the other based on a febantel-pyrantel embonate-praziquantel combination (DRONTAL) Plus; Group 2), was compared in a study involving 104 suckling pups from three different kennels. The animals in Group 1 were treated at a minimum milbemycin oxime dose of 0.5 mg/kg bw starting at 2 weeks of age and subsequently every 4 weeks until reaching 26 weeks of age. The animals in Group 2 were treated every 2 weeks from week 2 until week 12 of age and then once at week 26 at a minimum febantel and pyrantel embonate dose of 15.0 and 14.4 mg/kg bw, respectively. Toxocara egg counts were determined fortnightly starting at 2 weeks of age and continuing until 26 weeks of age for every pup. Any adverse drug event was recorded during the trial. Both treatment programmes significantly reduced the zoonotic Toxocara egg shedding and were well tolerated by the pups. The pups in Group 1 showed lower average faecal egg counts and were found more frequently shedding no eggs than the pups in Group 2.
Novartis Animal Health Inc., CH-4002 Basel, Switzerland.
R
R
Schenker
R
R
Cody
G
G
Strehlau
D
D
Alexander
P
P
Junquera
D000818:Animals; D000833:Animals, Suckling; D000871:Anthelmintics / Q000009:adverse effects / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000469:parasitology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000469:parasitology; D006146:Guanidines / Q000009:adverse effects / Q000627:therapeutic use; D018942:Macrolides / Q000009:adverse effects / Q000627:therapeutic use; D010270:Parasite Egg Count / Q000662:veterinary; D011716:Pyrantel Pamoate / Q000009:adverse effects / Q000627:therapeutic use; D017166:Toxocara canis / Q000187:drug effects*; D014120:Toxocariasis / Q000188:drug therapy* / Q000469:parasitology; D016896:Treatment Outcome
D000871:Anthelmintics; D006146:Guanidines; D018942:Macrolides; D011716:Pyrantel Pamoate; C027837:moxidectin; C017309:febantel